OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Decreased 1-year renal allograft survival is common in patients with postoperative acute tubular necrosis (ATN).
• Cyclosporine use can prolong ATN, while withholding it risks early rejection.
• Polyclonal antilymphocyte antibodies have been used to prevent rejection and avoid cyclosporine nephrotoxicity.

Purpose of the Study:

• To evaluate the efficacy of OKT3 monoclonal antibody prophylaxis in cadaveric renal allograft recipients experiencing ATN.
• To compare outcomes of OKT3 prophylaxis with early cyclosporine treatment in ATN patients.
• To compare outcomes with recipients experiencing immediate graft function.

Main Methods:

• Retrospective comparison of cadaveric renal allograft recipients with ATN.
• Group 1: Received OKT3 monoclonal antibody prophylaxis (n=26) starting January 1987.
• Group 2: Received cyclosporine treatment during ATN (n=40) in 1985-1986.

Main Results:

• 1-year graft survival was significantly higher with OKT3 prophylaxis (83%) versus early cyclosporine (55%).
• No significant difference in 1-year graft survival between OKT3-treated ATN patients and those with immediate graft function (74%).
• OKT3 prophylaxis shortened ATN duration (9.3 days vs 14.9 days) and prolonged median time to first rejection (23.5 days vs 11.0 days).

Conclusions:

• OKT3 monoclonal antibody prophylaxis offers superior 1-year graft survival in renal transplant recipients with ATN compared to early cyclosporine.
• OKT3 prophylaxis effectively manages ATN, reduces rejection risk, and improves graft outcomes.
• Patient survival was not affected by ATN or the immunosuppressive protocol used.